Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

Wang XiaoJing; Liu Yao; Wang XianBo

doi:10.3969/j.issn.1001-5256.2020.01.004

Volume 36 Issue 1

Jan. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(1): 26-30

PDF( 2123 KB)

Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2020.01.004

Department of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University

Research funding:

Received Date: 2019-12-20
Published Date: 2020-01-20

Abstract

Abstract

Primary biliary cholangitis(PBC) is an immune-mediated chronic and progressive intrahepatic cholestasis disease. Treatment with ursodeoxycholic acid(UDCA) can significantly improve the prognosis of patients with PBC,but some patients still have poor response to UDCA,which is the main risk factor for disease progression. Several evaluation models and scoring systems based on biochemical response have been applied to screen out patients with poor response in clinical practice. Integrated traditional Chinese and Western medicine therapy for PBC has certain advantages in improving the symptoms,liver biochemistry,fibrosis indices,and biochemical response rate of PBC patients and thus holds promise for clinical application; however,further improvement is needed for experimental design and efficacy evaluation.
- primary biliary cholangitis,
- biochemical response,
- TCM WM therapy

FullText(HTML)

门静脉高压症是肝硬化患者死亡的主要原因之一^[1]。据统计^[2]，确诊肝硬化门静脉高压症患者的第一年死亡率为25%~30%，如果不经过系统治疗，两年后的死亡率可高达50%。肝静脉压力梯度(hepatic venous pressure gradient, HVPG)是门静脉和下腔静脉之间的压力梯度^[3]，也是目前临床测量门静脉高压最可靠的方法^[4]。然而，由于HVPG属有创操作、检查费用高、技术难度大、难以重复检查等缺点，限制了其在临床实践中的广泛应用^[5]。目前，在临床中虽然涌现出了大量反映门静脉高压症的非侵入性方法，但其准确性及临床应用价值仍需进一步评估^[1]。肝活检仍是目前判断肝硬化及其分期的“金标准”，如果能够寻找其他的病理特征来反映门静脉压力，利用肝活检后的病理切片不仅能够用于肝纤维化程度判定，也能用来诊断门静脉高压的严重程度。近年来，研究发现，肝活检病理学的相关指标，如胶原面积、纤维间隔厚度、结节大小、微血管密度、胆管及淋巴管微结构的变化和门静脉高压症有良好的相关性，可为评估肝硬化门静脉高压症严重程度及制订进一步诊疗策略提供新的思路。

1.   HVPG与肝脏胶原面积、纤维间隔厚度及结节大小相关

胶原构成了肝脏结缔组织的细胞骨架^[6]。当肝脏受损时，肝小叶内原有的网状支架塌陷，肝星状细胞活化后转变为肌成纤维细胞并产生大量胶原^[7-8]，随着胶原沉积的增加，肝内阻力增大，门静脉压力也随之升高。健康人肝脏胶原约占肝质量的2%，肝硬化时可上升至8%~10%^[9]。一项动物实验研究^[10]发现，与门静脉压力＜10 mmHg的大鼠相比，显著门静脉高压(HVPG≥10 mmHg)大鼠肝脏的纤维面积升高了13倍。2009年Calvaruso等^[11]首次提出了利用组织切片的计算机辅助数字图像分析技术来测量胶原比例面积(collagen proportionate area, CPA)，从而反映肝脏纤维化的程度，他们通过对115例丙型肝炎患者的研究发现CPA不仅与纤维化程度相关，而且发现CPA与HVPG的组织学相关性甚至优于Ishak分期。随后，Tsochatzis等^[12]通过Laennec、Kuma、Nagula和Sethasine等半定量分类系统对从肝纤维化到肝硬化进行分期，发现CPA在肝硬化的所有阶段都成比例增加。随后，在一项对42例肝硬化患者进行肝活检，并在肝活检后6个月内进行HVPG测量的研究^[13]也发现CPA与HVPG显著相关(r=0.636，P＜0.005)。另外，在一项纳入169例感染慢性HBV或HCV的肝移植患者的研究^[14]中，在患者进行肝移植前后分别进行肝活检，发现CPA与HVPG相关(R²=0.41，P=0.01)。不仅如此，Nielsen等^[15]利用CPA可靠的区分了“临床上显著的门静脉高压”，即HVPG≥10 mmHg(受试者工作特征曲线下面积：0.923，P＜0.001；OR=1.209，P=0.003)。除此之外，纤维间隔厚度及结节大小与HVPG亦相关^[16]。一项回顾性研究^[17]对104例多种病因肝硬化患者进行肝活检，并在活检后1个月内进行了HVPG测定，发现HVPG与肝硬化的结节大小(P＜0.001)、间隔增厚(P=0.015)呈显著正相关。Nagula等^[18]通过对43例肝硬化患者测量HVPG，并评估了纤维间隔厚度及结节大小，发现小结节和纤维间隔厚度是独立预测“临床上显著的门静脉高压”的良好参数。利用胶原面积、纤维间隔厚度及结节大小来反映门静脉高压，目前仍处于研究阶段、缺乏大规模临床数据验证，不能完全替代目前临床上诊断门静脉高压的方法^[19]。但其为以后的临床研究奠定了基础，为预测肝硬化的进展和预后提供了新的思路。

2.   HVPG与肝内血管的变化有关

肝微血管的改变被认为是肝硬化门静脉高压症的重要病理生理特征之一^[20]。在门静脉高压症的发病机制中起着重要作用^[21]。门静脉高压时肝内血管的改变主要包括血管新生和血管重塑^[22]。在肝硬化的发展过程中，随着胶原的沉积、再生结节的形成，组织缺氧进一步加重，肝内微血管狭窄，甚至闭塞，进而导致肝内循环阻力增加，血管的这一系列改变又加剧了门静脉高压的严重程度^[23-24]。目前，对血管数量的计算主要采用“热点法”^[25]，免疫组化指标主要包括CD31、CD34以及vWF^[26]。有研究通过使用CD34抗体对肝组织切片进行染色，在二维层面证实了微血管密度(microvessel density, MVD)随着肝纤维化的发展不断升高(轻度纤维化的MVD为1.09%±0.26%，中度纤维化为1.92%±0.20%，重度纤维化为2.46%±0.23%)，均明显高于正常组(0.45%±0.14%) (P＜0.01)^[20]。此外，一项动物实验研究^[10]通过用CD34免疫染色方法测量肝硬化大鼠肝脏MVD，发现当门静脉压力升高时，新生血管数量亦增加，MVD与门静脉压力(r=0.731，P＜0.001)相关。胡春红团队^[20]通过近年来逐渐发展起来的一项对肝脏内部无创、三维可视化观察的一项新技术——X射线相衬CT对肝纤维化大鼠肝脏进行检查，在三维层面发现在肝纤维化的发展过程中，血管内壁的曲线度、纹理特征、内径和MVD与纤维化面积(r≥0.729，P＜0.001)和门静脉压力(r≥0.715，P＜0.001)有很好的相关性。随后，其团队通过这项技术再次对CCl₄或胆管结扎诱导的肝硬化大鼠的肝脏进行检查，发现门静脉压力与肝内血管分支形态特征显著相关(r≥0.761，P＜0.01)，证明了血管形态的改变能准确区分肝硬化大鼠的门静脉压力^[27]。并提出了门静脉分支形态学特征可作为门静脉高压症检测的替代指标。目前肝硬化的微血管改变与门静脉高压症的关系仅在动物实验中进行，尚缺少临床验证。但利用肝内微血管的改变来评估门静脉压力或预测门静脉高压症是非常有潜力的组织病理学指标。

3.   HVPG与淋巴管的变化有关

肝脏是产生淋巴液的最大器官^[28]，肝硬化肝脏血液动力学严重异常时，淋巴系统则发挥了重要的代偿作用^[29]。肝纤维化时，胶原的沉积和血管阻力的增加导致肝脏微循环障碍，从而导致淋巴系统在淋巴管新生、淋巴液产生、淋巴引流系统的扩张、淋巴液含量等方面的一系列变化^[30-31]。早在1984年就有研究^[32]发现肝硬化大鼠肝脏的淋巴液流量较对照组正常大鼠增加29倍，且淋巴流量与门静脉压力之间有良好的相关性(r=0.72~0.92，P＜0.01)。1997年Vollmar等^[33]首次报道了肝纤维化和肝硬化时淋巴管的新生。他们使用CCl₄大鼠肝硬化模型，发现在肝硬化形成过程中淋巴管密度逐渐增加，在CCl₄诱导后1、2和4周淋巴管密度的平均值分别为(12.3±8.0)、(19.9±10.4)和(49.8±9.0)cm，淋巴管面积由(2.6±1.7)%逐渐增加至(6.5±3.4)%和(14.5±1.7)%，与对照组相比均P＜0.01。Tanaka等^[34]对肝硬化患者的研究发现，随着淋巴管的新生，肝脏淋巴液的生成增加了30倍。在之后的临床研究^[28]中，也证明了在包括肝硬化在内的多种肝病患者中，肝淋巴管的生成显著增加。Yamauchi等^[35]对慢性病毒性肝炎和肝硬化患者的标本进行形态计量学分析，发现淋巴管的数量和面积均随肝纤维化程度的加重而增加。在一项纳入了28例不同病因的终末期肝病患者的研究^[36]中，通过使用podoplanin标记淋巴管，INFORM软件计算淋巴管密度，发现肝硬化患者淋巴管密度显著增加(P＜0.01)。Oikawa等^[37]报道特发性门静脉高压患者较健康对照组肝脏淋巴管的面积增加，推测可能与门静脉血流量减少有关。除此之外，Park等^[38]通过胸部CT测量179例慢性肝病患者的远端胸导管的直径发现，胸导管扩张程度与肝硬化进展及门静脉高压症进展有显著相关性(OR=3.809，95%CI：1.172~12.458，P=0.027和OR=2.788，95%CI：1.051~7.393，P=0.039)。然而，目前对淋巴系统在肝硬化和门静脉高压症中的作用机制仍不清楚，还需要进一步的研究。

4.   HVPG与胆管变化有关

肝脏除了血管、淋巴管系统，还拥有胆管这一特殊系统。目前，在多种肝硬化动物模型及不同病因肝硬化患者中均可见胆管增生^[39-40]。胆管增生的激活被认为在肝纤维化的发生和发展中起着关键作用^[41-42]。增生的胆管通过介导星状细胞增殖、活化，加快门静脉高压症的形成^[43-44]。Rókusz等^[45]分别用CK19免疫荧光标记和Picro Sirius染色后形态计量学方法检测肝硬化小鼠的胆管增生和纤维化程度，发现肝纤维化程度与胆管增生之间有很强的相关性(P＜0.001)。不仅仅在动物模型中，在一系列临床研究中，也证明了随着肝纤维化的发展，胆管数量逐渐增加。Wood等^[46]在对血色病患者的研究中，发现通过CK7标记的胆管数量随着纤维化程度而增加，两者呈正相关(r＝0.803，P＜0.0001)。在慢性丙型肝炎肝硬化患者中，CK7标记的胆管面积与纤维化程度亦呈正相关(r＝0.453，P＜0.000 1)^[47]。此外，在非酒精性脂肪性肝硬化中，随着肝纤维化程度的加重，CK7标记的胆管面积也呈现动态变化并且两者有密切相关性(r＝0.51，P＜0.000 1)^[48]。在丙型肝炎肝纤维化形成过程中，胆管的数量与肝纤维化阶段之间也呈正相关(r=0.53，P＜0.000 01)。胆管的数量随着肝纤维化的发展而增加^[40]。虽然肝硬化时胆管的形态数量改变的研究仍处于理论阶段，但通过计算病理切片中胆管的面积，能够反映肝纤维化程度。为胆管形态和数量的变化预测门静脉压力提供了理论基础，也将成为一项非常有潜力的病理学指标。

5.   研究现状及展望

肝硬化在病理上不仅表现为胶原沉积、血管新生，同时也伴有胆管和淋巴管的增生。而门静脉高压症是肝硬化失代偿期患者死亡的重要原因。近年来，许多研究已经证明肝硬化门静脉高压症时，肝内胶原面积、纤维间隔厚度、结节大小、微血管密度及淋巴管、胆管密度和面积与门静脉高压症有良好的相关性，并且通过二维病理及其三维结构证实了这些发现。这是对肝硬化的病理形态学特点的补充，不仅为肝脏穿刺活检提供了更多的临床价值，为肝活检评估肝硬化严重程度提供了一个新的病理指标，也为门静脉高压症的诊断提供了新的思路。

References(40)

References

[1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[2] LINDOR KD,BOWLUS CL,BOYER J,et al. Primary biliary cholangitis:2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2019,69(1):394-419.

[3] HIRSCHFIELD GM,DYSON JK,ALEXANDER GJM,et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut,2018,67(9):1568-1572.

[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol,2017,67(1):145-172.

[5] HARMS MH,LAMMERS WJ,THORBURN D,et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis:Risk factors and time trends in incidence and outcome[J]. Am J Gastroenterol,2018,113(2):254-264.

[6] CARBONE M,MELLS GF,PELLS G,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology,2013,144(3):560-569.

[7] MARSCHALL HU,HENRIKSSON I,LINDBERG S,et al. Incidence,prevalence,and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort[J]. Scientific reports,2019,9(1):11525.

[8] CHEN S,DUAN W,LI M,et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis:A single center follow-up study from China[J]. J Gastroenterol Hepatol,2019,34(7):1236-1241.

[9] CHEUNG AC,LAMMERS WJ,MURILLO PEREZ CF,et al.Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol,2019,17(10):2076-2084.

[10] YOO JJ,CHO EJ,LEE B,et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio[J]. Gut Liver,2018,12(6):714-721.

[11] CHEUNG KS,SETO WK,FUNG J,et al. Prognostic factors for transplant-free survival and validation of prognostic models in chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid[J]. Clin Transl Gastroenterol,2017,8(6):e100.

[12] HUANG C,HAN W,WANG C,et al. Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis:A meta-analysis[J]. Disease markers,2019,2019:9121207.

[13] NAKAMURA M,KOMORI A,ITO M,et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary[J]. Hepatol Res,2007,37(3):412-419.

[14] TAKANO K,SAEKI C,OIKAWA T,et al. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate[J]. J Gastroenterol Hepatol,2019.[Epub ahead of print]

[15] MURILLO PEREZ CF,HIRSCHFIELD G,CORPECHOT C,et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response[J]. Aliment Pharmacol Ther,2019,50(10):1127-1136.

[16] LIU X,XU H,ZHAN M,et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis[J]. Med Sci Monit,2019,25:6174-6180.

[17] NI P,MEN R,SHEN M,et al. Concomitant Sjgren’s syndrome was not associated with a poorer response or outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Can J Gastroenterol Hepatol,2019,2019:7396870.

[18] ANGULO P,DICKSON ER,THERNEAU TM,et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis:A randomized trial[J]. J Hepatol,1999,30(5):830-835.

[19] CORPECHOT C,CARRAT F,POUJOL-ROBERT A,et al.Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis[J].Hepatology,2012,56(1):198-208.

[20] LAMMERS WJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validat ion of a scoring system to predict outcomesof patients with primary biliary cirrhosis receiving ursodeox ycholic acid therapy[J]. Gastroenterology,2015,149(7):1804-1812.

[21] CARBONE M,SHARP SJ,FLACK S,et al. The UKPBC risk scores:Derivation and validat ion of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis[J]. Hepatology,2016,63(3):930-950.

[22] EFE C,TA爦ILAR K,HENRIKSSON I,et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Am J Gastroenterol,2019,114(7):1101-1108.

[23] CHEN J,XUE D,GAO F,et al. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment[J]. Eur J Gastroenterol Hepatol,2018,30(11):1352-1360.

[24] HIRSCHFIELD GM,MASON A,LUKETIC V,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology,2015,148(4):751-761.

[25] KOWDLEY KV,LUKETIC V,CHAPMAN R,et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology,2018,67(5):1890-1902.

[26] CHEN JL,YANG X,ZHANG Q,et al. Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis:A realworld cohort study[J]. Chin J Hepatol,2018,26(12):909-915.(in Chinese)陈佳良，杨雪，张群，等．熊去氧胆酸联合中药治疗对原发性胆汁性胆管炎患者生物化学应答的影响:一项基于真实世界的队列研究[J]．中华肝脏病杂志，2018,26(12):909-915.

[27] ZHANG RM,ZHANG T,WU JH,et al. Clinical effect of liversoothing,cholagogic,spleen-strengthening,and bloodactivating therapy combined with ursodeoxycholic acid in treatment of primary biliary cholangitis[J]. Fujian Med J,2019,41(2):27-30.(in Chinese)张如棉，章亭，吴剑华，等．疏肝利胆健脾活血法联合熊去氧胆酸治疗原发性胆汁性胆管炎的临床疗效[J]．福建医药杂志，2019,41(2):27-30.

[28] WU XX,LI X,DANG ZQ,et al. Efficacy of Shugan Lidan Tang combined ursodeoxycholic acid in treating early and midterm primary biliary cirrhosis[J]. Chin J Exp Med Formul,2018,24(12):175-181.(in Chinese)吴秀霞，李鲜，党中勤，等．疏肝利胆汤加减联合熊去氧胆酸治疗早、中期原发性胆汁性肝硬化的临床观察[J]．中国实验方剂学杂志，2018,24(12):175-181.

[29] ZENG WW,WU XJ. Effect of Hugan Zhuyu decoction combined with ursodeoxycholic acid on immunoglobulin and T lymphocyte subsets in patients with primary biliary cirrhosis[J].Chin J Gen Pract,2019,17(3):464-467.(in Chinese)曾武武，吴学杰．护肝逐瘀汤联合熊去氧胆酸对原发性胆汁性肝硬化患者免疫球蛋白及T淋巴细胞亚群的影响[J]．中华全科医学，2019,17(3):464-467.

[30] XIAO LH,HU XY. Clinical effect of Lidan Yanggan prescription combined with ursodeoxycholic acid capsules in treatment of primary biliary cirrhosis[J]. Beijing J Tradit Chin Med,2018,37(6):553-555,561.(in Chinese)肖玲辉，扈晓宇．利胆养肝方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化临床观察[J]．北京中医药，2018,37(6):553-555,561.

[31] XIA XY,SHI Y. Efficacy of Qinggan Lidan decoction combined with fenofibrate in the treatment of primary cholangitis with poor response to ursodeoxycholic acid and its effect on Th1/Th2lymphocyte imbalance[J]. Mod J Integr Tradit Chin West Med,2019,28(21):2313-2316,2322.(in Chinese)霞晓燕，石勇．清肝利胆方配合非诺贝特对熊去氧胆酸应答不佳的原发性胆汁性胆管炎应答率及Th1/Th2淋巴细胞失衡的影响[J]．现代中西医结合杂志，2019,28(21):2313-2316,2322.

[32] LIN L,YU XF,CHEN GL. Clinical effect of Qiwei Huaxian decoction combined with ursodeoxycholic acid in treatment of stage II/III primary biliary cirrhosis with spleen deficiency and blood stasis[J]. Tradit Chin Med J,2015,14(5):50-52.(in Chinese)林立，俞晓芳，陈国良．七味化纤汤联合熊去氧胆酸治疗Ⅱ、Ⅲ期脾虚血瘀型原发性胆汁性肝硬化的临床观察[J]．中医药通报，2015,14(5):50-52.

[33] HUANG LY,ZHOU ZH,SUN XH,et al. Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis[J]. J Clin Hepatol,2015,31(2):181-184.(in Chinese)黄凌鹰，周振华，孙学华，等．复方鳖甲软肝片治疗原发性胆汁性肝硬化的临床疗效评价[J]．临床肝胆病杂志，2015,31(2):181-184.

[34] JIANG XY,WU WJ,OU Y. Clinical effect of Fuzheng Huayu capsules combined with ursodeoxycholic acid in treatment of primary biliary cholangitis[J]. Med Forum,2019,23(25):3667-3668.(in Chinese)江晓燕，吴文杰，欧旸．扶正化瘀胶囊合并熊去氧胆酸对原发性胆汁性胆管炎的治疗效果观察[J]．基层医学论坛，2019,23(25):3667-3668.

[35] GAO F,XUN J,JIAO JL,et al. Clinical effect of Fuzheng Huayu capsules combined with ursodeoxycholic acid capsules in treatment of primary biliary cirrhosis[J]. J Shanxi Med Coll Contin Educ,2015,25(6):17-19.(in Chinese)高峰，荀健，焦记丽，等．扶正化瘀胶囊联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的临床观察[J]．山西职工医学院学报，2015,25(6):17-19.

[36] XI Q,SONG CR,LIU YZ,et al. Study on treatment of primary biliary cirrhosis by Jianpi Huoxue Decocition combined with ursodeoxycholic acid capsules[J]. Mod J Integr Tradit Chin West Med,2016,25(3):242-244,283.(in Chinese)席奇，宋春荣，刘亚珠，等．健脾活血方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的研究[J]．现代中西医结合杂志，2016,25(3):242-244,283.

[37] CHEN XQ,CAO HF. Regulatory effect of Lidan Qushi prescription on peripheral blood T lymphocyte subsets in patients with primary biliary cirrhosis with liver-gallbladder dampheat[J]. J Sichuan Tradit Chin Med,2018,36(11):103-105.(in Chinese)陈秀清，曹海芳．利胆祛湿方对肝胆湿热型原发性胆汁性肝硬化患者外周血T细胞亚群的调节作用[J]．四川中医，2018,36(11):103-105.

[38] JIANG XY,TANG HH,WEI CS,et al. Treatment of 31 cases of primary biliary cholangitis with ruangan decoction combined with ursodeoxycholic acid[J]. Mod Tradit Chin Med,2018,38(6):33-35,39.(in Chinese)姜小艳，唐海鸿，魏春山，等．软肝汤联合熊去氧胆酸治疗原发性胆汁性胆管炎31例[J]．现代中医药，2018,38(6):33-35,39.

[39] YANG L,LI Y,YUAN XX,et al. Effect of Yangyin Tongluo Decoction on primary biliary cholangitis and its influence on cytokines[J]. Chin J Integr Trad West Med Dig,2017,25(9):646-650,655.(in Chinese)杨磊，李莹，袁星星，等．养阴通络汤对原发性胆汁性胆管炎临床疗效及对细胞因子的影响[J]．中国中西医结合消化杂志，2017,25(9):646-650,655.

[40] GAN X,ZHAO XF,LIN H,et al. Efficacy of Qingying Huoxue decoction in treating primary biliary cirrhosis with liver-gallbladder dampness-heat syndrome and effect on Th17/Treg balance in peripheral blood[J]. Chin J Exp Med Formul,2016,22(11):161-164.(in Chinese)甘霞，赵新芳，林红，等．清营活血汤对原发性胆汁性肝硬化肝胆湿热型的疗效以及对外周血Th17/Treg平衡的影响[J]．中国实验方剂学杂志，2016,22(11):161-164.

Relative Articles

[1]	Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
[2]	Li Yang, Shu DeJun, Peng CiJun, Feng ZanJie, Mei Yong, Xiong Kun. Effect of erythropoietin on the mRNA expression of apoptosis genes bcl-2 and bax in rats with fatty liver disease after hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 157-160. doi: 10.3969/j.issn.1001-5256.2019.01.030
[3]	Liu Jian, Li Li, Wang XiaoChuan, Zhang ShengNing, Li LaiBang, Mang YuanYi, Gao Yang, Chen YongLin, Ren Gang, Li Wang. Mild hypothermia exerts a protective effect against hepatic ischemia-reperfusion injury in rats by activating the PI3K/Akt signaling pathway[J]. Journal of Clinical Hepatology, 2019, 35(4): 846-851. doi: 10.3969/j.issn.1001-5256.2019.04.027
[4]	Lu Xin, Liu Ying, Jia Lei, Kong LingYu, Liu DianQing. Role of D-bifunctional protein in promoting the growth of hepatocellular carcinoma in rats and nude mice[J]. Journal of Clinical Hepatology, 2019, 35(7): 1532-1535. doi: 10.3969/j.issn.1001-5256.2019.07.022
[5]	Luo YanQing, Feng ChunLin, Mei Yong, Du Chao, Ceng PengFei, Wang Jun, Wang GuoXing, Zhao Liang, Leng Kai. Protective effect of hepatocyte growth-promoting factor against liver ischemia-reperfusion injury in rats and its mechanism of action[J]. Journal of Clinical Hepatology, 2019, 35(2): 364-367. doi: 10.3969/j.issn.1001-5256.2019.02.024
[6]	Pan Qi, Luo ChunHai, Ma WanLing, Qu YuanFei, Wang JianRu, Chen Lin. Specific magnetic resonance imaging of vascular endothelial growth factor-C targeted molecular probe and its clinical significance in a rat model of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1492-1496. doi: 10.3969/j.issn.1001-5256.2018.07.025
[7]	Wu LinLan, Xu Bing, Wei JianWei, Zhao ZhiPing, Huang SuQin, Yang XiaoMei. Therapeutical effect of local transplantation of bone marrow mesenchymal stem cells mixed with fibrin gel on rats with liver injury[J]. Journal of Clinical Hepatology, 2018, 34(8): 1740-1744. doi: 10.3969/j.issn.1001-5256.2018.08.029
[8]	Liang Kai, Kong WeiZong, Chen Juan, Wang YingChun. Effect of trefoil factor 3 on intestinal mucous barrier in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1552-1557. doi: 10.3969/j.issn.1001-5256.2017.08.029
[9]	Yang PuJuan, Huang Yi, Liu HuaBao. Research advances in the association between interleukin-17 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1810-1814. doi: 10.3969/j.issn.1001-5256.2017.09.041
[10]	Li KeXin, Zang MengYa, Wang DongMei, He Huan, Wang YuTing, Qu ChunFeng. Effect of interleukin-17A on stemness of hepatoma cell lines[J]. Journal of Clinical Hepatology, 2017, 33(6): 1131-1136. doi: 10.3969/j.issn.1001-5256.2017.06.023
[11]	Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
[12]	Cao ZhenHuan, Liu YaLi, Ma LiNa, Lu JunFeng, Jin Yi, He ZhiMin, Zheng YanHong, Chen XinYue. Association between serum level of interleukin-17 and HBsAg clearance in patients with HBsAg-negative chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1292-1295. doi: 10.3969/j.issn.1001-5256.2016.07.015
[13]	Xiong Yan, Zhang ZhiJuan, Liu Peng, Wang Ya. Efficacy of Chaowei Zhikangyin in treatment of rat model of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(1): 78-81. doi: 10.3969/j.issn.1001-5256.2015.01.017
[14]	Lai JieYing, Song SiYu, Hao LiPing, Zhang XiaoLi. Localization and therapeutic effect of bone marrow hematopoietic cell transplantation in rat model of liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1878-1882. doi: 10.3969/j.issn.1001-5256.2015.11.026
[15]	Li CaiDong, Yang YongWei, Li HuiJun, Tian PengFei, Wu Bin. Changes in peripheral plasma concentrations of macrophage migration inhibitory factor,interleukin-17,and interleukin-10 and their correlations with HBV DNA load in chronic HBV carriers[J]. Journal of Clinical Hepatology, 2015, 31(5): 702-705. doi: 10.3969/j.issn.1001-5256.2015.05.017
[16]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[17]	Wang YingChun, Kong WeiZong, Jin QingMei, Chen Juan. Effect of salvianolic acid B on hepatocyte apoptosis in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1325-1329. doi: 10.3969/j.issn.1001-5256.2014.12.022
[18]	Zhao RongRong, Yang XiaoFei, Dong Jie, Huang ZhangXing, Zhang Ye, Lian JianQi. Toll- like receptor 2 drives Th17 cell activation in inflammatory response to hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2014, 30(9): 877-881. doi: 10.3969/j.issn.1001-5256.2014.09.010
[19]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[20]	Qin JianJie, Lu: Ling. The role and molecular mechanism of interleukin-17 in organ transplant rejection[J]. Journal of Clinical Hepatology, 2012, 28(11): 812-814.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	史华，何志威，甘轲. 血清TIMP-1、M-CSF联合检测对老年病人乙型肝炎后肝硬化早期诊断的价值. 实用老年医学. 2024(06): 607-611 .
2.	李芸茜，李俊，曹政. 内镜超声在肝硬化门脉高压症诊治中的研究进展. 胃肠病学和肝病学杂志. 2024(06): 783-788 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1557) PDF downloads(300)

Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2020.01.004

Abstract

1. HVPG与肝脏胶原面积、纤维间隔厚度及结节大小相关

2. HVPG与肝内血管的变化有关

3. HVPG与淋巴管的变化有关

4. HVPG与胆管变化有关